NM_024675.4:c.1699C>T
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_024675.4(PALB2):c.1699C>T(p.His567Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000657 in 1,612,190 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152162Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000689 AC: 17AN: 246902Hom.: 0 AF XY: 0.0000672 AC XY: 9AN XY: 133978
GnomAD4 exome AF: 0.0000692 AC: 101AN: 1460028Hom.: 0 Cov.: 32 AF XY: 0.0000688 AC XY: 50AN XY: 726334
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152162Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1Benign:4
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
- -
- -
- -
not provided Uncertain:3
In the published literature, this variant has been reported in individuals affected with breast and/or ovarian cancer (PMIDs: 22241545 (2012), 25186627 (2015), 33471991 (2021) see also LOVD (http://databases.lovd.nl/PALB2), 35263119 (2022)) and in healthy individuals (PMIDs: 26283626 (2015), 26315354 (2015), 33471991 (2021) see also LOVD (http://databases.lovd.nl/PALB2)). The frequency of this variant in the general population, 0.001 (10/9914 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
- -
In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer, as well as unaffected controls (Tischkowitz et al., 2012; Tung et al., 2015; Dorling et al., 2021); This variant is associated with the following publications: (PMID: 25186627, 22241545, 26283626, 26315354, 31843900, 33471991) -
Familial cancer of breast Uncertain:2Benign:1
- -
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitters to LOVD: Marc Tischkowitz, Melissa DeRycke. -
- -
not specified Uncertain:1Benign:2
- -
- -
Variant summary: PALB2 c.1699C>T (p.His567Tyr) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.7e-05 in 1620186 control chromosomes, predominantly at a frequency of 0.00018 within the South Asian subpopulation in the gnomAD database. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 1.15 fold of the estimated maximal expected allele frequency for a pathogenic variant in PALB2 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (0.00016). Further, 3 individuals carried this variant in the FLOSSIES database (women >70 years of age with no personal history of cancer). c.1699C>T has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome as well as in controls (Tischkowitz_2012, Thompson_2015, Ramus_2015, Tung_2015, Dorling_2021, Delahunty_2022). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 35263119, 33471991, 26315354, 26283626, 22241545, 25186627, 31843900, 38439815). ClinVar contains an entry for this variant (Variation ID: 126622). Based on the evidence outlined above, the variant was classified as likely benign. -
PALB2-related disorder Uncertain:1
The PALB2 c.1699C>T variant is predicted to result in the amino acid substitution p.His567Tyr. This variant has been reported in several individuals with breast cancer (Tischkowitz et al. 2012. PubMed ID: 22241545; Tung et al. 2015. PubMed ID: 25186627; Breast Cancer Association Consortium et al. 2021. PubMed ID: 33471991), but it has also been documented in multiple unaffected individuals in several large breast/ovarian cancer case-control studies (Thompson et al. 2015. PubMed ID: 26283626; Ramus et al. 2015. PubMed ID: 26315354; Breast Cancer Association Consortium et al. 2021. PubMed ID: 33471991). This variant is reported in 0.10% of alleles in individuals of Ashkenazi Jewish descent in gnomAD and has conflicting interpretations in ClinVar ranging from benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/126622). Although we suspect that this variant may be benign, the clinical significance of this variant is uncertain at this time due to the absence of conclusive functional and genetic evidence. -
Fanconi anemia complementation group N Uncertain:1
This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at